Evaluation of carbon-11 labeled 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide as PET tracer for imaging of CSF-1R expression in the brain.

Bioorganic & Medicinal Chemistry
Berend van der WildtFrederick T Chin

Abstract

Pharmacological targeting of tumor associated macrophages and microglia in the tumor microenvironment is a novel therapeutic strategy in the treatment of glioblastoma multiforme. As such, the colony stimulating factor-1 receptor (CSF-1R) has been identified as a druggable target. However, no validated companion diagnostic marker for these therapies exists to date. Towards development of a CSF-1R PET tracer, a set of six compounds based on recently reported CSF-1R inhibitor 5-(1-methyl-1H-pyrazol-4-yl)-N-(2-methyl-5-(3-(trifluoromethyl)benzamido)phenyl)nicotinamide (Compound 5) was designed, synthesized and evaluated in vitro for potency and selectivity. The highest affinity for CSF-1R was found for compound 5 (IC50: 2.7 nM). Subsequent radiosynthesis of [11C]5 was achieved in 2.0 ± 0.2% yield (decay corrected to start of synthesis) by carbon-11 carbon monoxide aminocarbonylation in 40 min after end of bombardment. In vitro autoradiography with [11C]5 on rat brain sections demonstrated high specific binding, but also strong off-target binding. Ex vivo, only intact tracer was observed in blood plasma at 90 min post injection in healthy rats. PET scanning results demonstrated negligible brain uptake under baseline conditions and t...Continue Reading

References

Feb 20, 2007·Nuclear Medicine and Biology·Kun-Eek KilJoanna S Fowler
Feb 5, 2008·Bioorganic & Medicinal Chemistry Letters·Carl R IlligSanath K Meegalla
Jul 18, 2008·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Jens P BankstahlOliver Langer
Jul 7, 2012·Drug Discovery Today·Paul SlobbeGuus A M S van Dongen
Sep 24, 2013·Nature Medicine·Stephanie M PyonteckJohanna A Joyce
Nov 28, 2013·Bioorganic & Medicinal Chemistry·Zhenghong PengWilliam G Bornmann
Jan 11, 2014·Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine·Vladimir TolmachevAnna Orlova
Sep 27, 2014·Bioorganic & Medicinal Chemistry Letters·Vadim Bernard-Gauthier, Ralf Schirrmacher
Dec 17, 2014·Journal of Medicinal Chemistry·Zoran Rankovic
Mar 31, 2015·Journal of Labelled Compounds & Radiopharmaceuticals·Kenneth DahlChrister Halldin
Apr 14, 2016·Nuclear Medicine and Biology·Berend van der WildtAlbert D Windhorst
Apr 17, 2016·Trends in Neurosciences·Violeta ChituE Richard Stanley
Apr 6, 2017·Bioorganic & Medicinal Chemistry Letters·Sreekanth A RamachandranRoopa Rai
Sep 7, 2017·Current Oncology Reports·Florent PeyraudAntoine Italiano
Nov 21, 2017·Nature Reviews. Immunology·Qingyun Li, Ben A Barres
Oct 5, 2018·Journal of Labelled Compounds & Radiopharmaceuticals·Berend Van der WildtFrederick T Chin
Jan 13, 2019·Proceedings of the National Academy of Sciences of the United States of America·Andrew G HortiMartin G Pomper
Feb 23, 2019·Chemical Communications : Chem Comm·Berend van der WildtFrederick T Chin

❮ Previous
Next ❯

Citations

Aug 1, 2021·Clinical and Experimental Immunology·Wissam BeainoAlbert D Windhorst

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.

Related Papers

Applied Immunohistochemistry & Molecular Morphology : AIMM
Huiyuan GuanZhenning Wang
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
M G MaherB G Haffty
Proceedings of the National Academy of Sciences of the United States of America
Kim N Green, David A Hume
© 2021 Meta ULC. All rights reserved